KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $32.60.

A number of equities analysts have commented on the stock. Citizens Jmp cut their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Thursday, March 26th. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Finally, Stifel Nicolaus boosted their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 9,550 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $193,101.00. Following the completion of the sale, the chief executive officer directly owned 462,577 shares in the company, valued at approximately $9,353,306.94. The trade was a 2.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,862 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the completion of the sale, the insider owned 51,391 shares of the company’s stock, valued at approximately $1,039,126.02. The trade was a 3.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 263,969 shares of company stock worth $4,536,178. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. State Street Corp raised its holdings in KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after buying an additional 336,195 shares during the last quarter. Vestal Point Capital LP raised its holdings in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the last quarter.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for about $1.9 billion and to buy shares for $27.00 in cash — the deal highlights Chiesi’s push into rare-disease/HAE treatment Ekterly and is the primary catalyst for the stock’s jump. Chiesi to buy KalVista in $1.9B deal
• Positive Sentiment: Market reaction: shares surged roughly 38–39% on the takeover news and trading volume spiked well above average, reflecting investor demand to capture the cash takeover consideration. KalVista stock surges 39%
• Neutral Sentiment: Trading mechanics: trading in KALV was temporarily halted prior to the announcement for “news pending,” a routine step that precedes major corporate news and can amplify post-release moves. (Company/regulatory filings reflected the halt.)
• Neutral Sentiment: Analyst view: Needham & Company reaffirmed a “hold” rating on KalVista — a reminder some analysts view the takeover price as fair or limited upside beyond the offer. Needham reaffirms hold
• Negative Sentiment: Litigation risk: multiple shareholder-alerts and law-firm investigations (Ademi LLP and Monteverde & Associates) have been announced questioning whether the $27.00 per-share deal is fair and whether fiduciary duties were met — these actions could delay closing, prompt a negotiated price change, or produce settlement costs. Ademi LLP shareholder alert Monteverde investigation

KalVista Pharmaceuticals Price Performance

KALV stock opened at $26.66 on Friday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals has a one year low of $9.83 and a one year high of $26.76. The stock has a market cap of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40. The firm has a 50 day simple moving average of $18.45 and a two-hundred day simple moving average of $15.72.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.